Welcome to our dedicated page for Innate Pharma SA SEC filings (Ticker: IPHA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Innate Pharma S.A.'s filings document the company's foreign private issuer reporting, oncology pipeline disclosures, governance matters, and share-capital information. Form 6-K reports furnish company press releases covering clinical-stage immunotherapy programs, business updates, investor and scientific conference activity, Annual General Meeting materials, and French share and voting-right notifications.
The company's Form 20-F annual report and Universal Registration Document address annual financial reporting, management discussion, corporate governance, statutory auditor reports, and risk factors for a biotechnology issuer developing antibody therapeutics. Filings also reference registration statements on Form F-3 and Form S-8 and disclose Nasdaq and Euronext Paris trading identifiers.
Innate Pharma S.A. furnished a Form 6-K as a foreign private issuer, providing its H1 2025 Half-Year Financial Report for the period from January 1 to June 30, 2025. The half-year report is attached as Exhibit 99.2 and contains the company’s detailed financial and operating information.
The company states that this Form 6-K and Exhibit 99.2 (excluding the statutory auditors' review report on page 49) are incorporated by reference into its existing registration statements on Form F-3 and Form S-8, meaning the half-year information becomes part of those U.S. securities offering documents.